

Zydus receives final approval from the USFDA for Mycophenolate Mofetil for Injection USP

Ahmedabad, 2 September 2017

Zydus Cadila has received the final approval from the USFDA to market Mycophenolate Mofetil for Injection USP, 500 mg/vial. The drug is indicated for use in combination with other drugs i.e., cyclosporine and corticosteroids for the prophylaxis of organ rejection in patients receiving renal, hepatic or cardiac transplants. The drug will be manufactured at the group's formulations manufacturing facility at Moraiya, Ahmedabad.

The group now has more than 140 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.
